Audentes Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Audentes Therapeutics's estimated annual revenue is currently $26.7M per year.
- Audentes Therapeutics received $172.5M in venture funding in October 2018.
- Audentes Therapeutics's estimated revenue per employee is $67,323
- Audentes Therapeutics's total funding is $531.4M.
Employee Data
- Audentes Therapeutics has 396 Employees.
- Audentes Therapeutics grew their employee count by -4% last year.
Audentes Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Clinical Development | Reveal Email/Phone |
2 | SVP/Chief Scientific Officer | Reveal Email/Phone |
3 | Associate Director, Program Management | Reveal Email/Phone |
4 | Associate Director, Clinical Science | Reveal Email/Phone |
5 | Sr. Manager, Validation | Reveal Email/Phone |
6 | Senior Manager, Downstream Process Development | Reveal Email/Phone |
7 | Clinical Trial Manager II | Reveal Email/Phone |
8 | Project Manager, Research Operations | Reveal Email/Phone |
9 | Sr. Manager, IT Infrastructure | Reveal Email/Phone |
10 | SVP/Regulatory Affairs | Reveal Email/Phone |
Audentes Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Audentes Therapeutics?
Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities. If you are interested in learning more about our company, please do not hesitate to contact us.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$531.4M
Total Funding
396
Number of Employees
$26.7M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Audentes Therapeutics News
Working with Nationwide Children's Hospital, Audentes Therapeuticsthe gene therapy startup Astellas bought for $3 billion in 2019...
Working with Nationwide Children's Hospital, Audentes Therapeuticsthe gene therapy startup Astellas bought for $3 billion in 2019...
BioXcel Therapeutics aims to become the leading ... Audentes Therapeuticsthe gene therapy startup Astellas bought for $3 billion in 2019...
Two patients in a study of a high-dose gene therapy for a rare muscle disorder have died, heightening worries about the safety of potent treatments under development for other diseases. Audentes Therapeutics, a San Francisco-based unit of the Japanese drug firm Astellas, told patient groups in ...
In trading on Wednesday, shares of Audentes Therapeutics Inc (Symbol: BOLD) entered into oversold territory, hitting an RSI reading of 28.9, ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $120.3M | 396 | 5% | N/A |
#2 | $71.8M | 396 | 0% | N/A |
#3 | $144.3M | 398 | 6% | N/A |
#4 | $122.2M | 399 | N/A | N/A |
#5 | $122.2M | 399 | -6% | N/A |
Audentes Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-07-22 | $30.0M | A | OrbiMed Advisors, 5AM Ventures | Article |
| 2014-12-03 | $42.5M | B | Deerfield Management | Article |
| 2015-10-14 | $65.0M | C | Sofinnova Ventures | Article |
| 2017-04-20 | $75.4M | Undisclosed | Multiple | Article |
| 2018-01-24 | $172.5M | Undisclosed | BofA Merrill Lynch | Article |
| 2018-01-26 | $231.4M | Undisclosed | BofA Merrill Lynch | Article |
| 2018-10-10 | $172.5M | Undisclosed | BofA Merrill Lynch | Article |